D-0493-2026 Class II Ongoing

Recalled by The Harvard Drug Group LLC — Dublin, OH

FDA drug recall D-0493-2026 was initiated by The Harvard Drug Group LLC on Apr 9, 2026 and is designated Class II. Reason for recall: Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells. The recall status is ongoing. Affected quantity: 2,238 5 x 10 unit dose cartons.

Recall details

Product Type
Drugs
Report Date
Apr 29, 2026
Initiation Date
Apr 9, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,238 5 x 10 unit dose cartons

Product description

Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose blister cards) per carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46288. NDC: 0904-7495-06

Reason for recall

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Distribution pattern

Nationwide in the USA

Code information

Lot#: Lot N02406, Exp 10/31/2026; Lot N02845, Exp 12/31/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0493-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0493-2026. Report a data issue: hello@regdatalab.com.